Talazoparib, another potent PARP inhibitor, was approved based on a Phase I trial (NCT03499353), which reported a median overall survival (OS) of 24.3 months in HER2‐negative advanced breast cancer patients, significantly outperforming the 6.3 months observed in those receiving standard chemotherapy. This evidence concerns the gene PARP1 and breast cancer.